Maynard Um
-
-
-
-
-
-
-
Stoke Therapeutics (STOK) PT Raised to $50 at H.C. Wainwright
-
-
-
-
-
-
-
Biogen and Stoke present 3-year zorevunersen data for Dravet syndrome
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Stoke Therapeutics (STOK)
-
-
-
-
-
-
-
BTIG Reiterates Buy Rating on Stoke Therapeutics (STOK)
-
-
-
-
-
-
-
Stoke Therapeutics Inc. (STOK) files mixed shelf
-
-
-
-
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

